Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy

Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript

Roivant Sciences Q4 Earnings Call Highlights

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's Why

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provide Business Update on Wednesday, May 20, 2026

Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026

Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy

Roivant Sciences Ltd. (NASDAQ:ROIV) Given Consensus Rating of “Moderate Buy” by Brokerages

Elevate Capital Advisors LLC Sells 36,236 Shares of Roivant Sciences Ltd. $ROIV

Montes Archimedes Acquisition (ROIV) Upgraded to Buy: Here's What You Should Know

Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV

Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint

Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data Update Transcript

Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

105,000 Shares in Roivant Sciences Ltd. $ROIV Acquired by Bamco Inc. NY

Roivant Sciences Ltd. (ROIV) Presents at Leerink Global Healthcare Conference 2026 Transcript

Roivant Sciences Ltd. (ROIV) Discusses $2.25 Billion Global Settlement Resolving COVID Vaccine Patent Litigation Transcript

Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With Moderna

Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna

Roivant Sciences Ltd. (ROIV) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Priovant Announces FDA Acceptance and Priority Review of New Drug Application for Brepocitinib in Dermatomyositis

Market Today: Nvidia beats, Meta chip deals, Amex HQ move

First Look: Nvidia in Focus, WBD Bid Drama, AMD--Meta Deal

Market Today: AMD--Meta AI pact, WBD bid war, Stripe at $159B

First Look: Gilead buys Arcellx; IBM sinks on AI; Bitcoin slides

Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Jefferies Group Exits Vanguard Information Technology ETF, Impacting Portfolio by -8.06%

Roivant Sciences Ltd. $ROIV Shares Bought by New York State Common Retirement Fund

Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year High – What’s Next?

Roivant: The Next Telavant Has Arrived With Brepocitinib's Blockbuster Data (Rating Upgrade)

Roivant Sciences Ltd. (ROIV) Q3 2025 Earnings Call Transcript

Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates

Roivant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025

Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)

Pulmovant Announces Completion of Enrollment in the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026

Campbell & CO Investment Adviser LLC Sells 68,705 Shares of Roivant Sciences Ltd. $ROIV

NovAccess Global (OTCMKTS:XSNX) versus Roivant Sciences (NASDAQ:ROIV) Financial Review

Roivant Sciences Ltd. (ROIV) Presents at 44th Annual J.P.

Roivant Sciences Ltd. (ROIV) Q2 2025 Earnings Call Transcript

First Look: 2026 Outlook, Buffett Exit, Fed Split, Dollar Slide